EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Re-programmed eosinophils drive allergic rhinitis via epigenetic and metabolic innate immune memory

Yun Liao, Yongmin Xie, Haiyang Han, Haoyue Zheng, Pingchang Yang, Gui Yang

Journal of Innate Immunity · 2026-11-10

DOI: 10.1159/jin/adhag005 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background: Allergic rhinitis (AR) is a prevalent recurrent upper airway inflammatory disorder. The lack of clarity on chronicity driving mechanisms hinders the development of precise treatments for severe, persistent allergic rhinitis. Objective: This study aimed to uncover the epigenetic and metabolic basis of sustained AR inflammation and identify key cellular drivers and therapeutic targets for refractory AR. Methods: We combined a two hit house dust mite (HDM) induced chronic AR mouse model and clinical samples from severe chronic AR patients. Integrated epigenetic profiling, metabolic assays, eosinophil depletion, IL 33–ST2 blockade, and clinical correlation analyses were performed to characterize pathogenic eosinophil programming. Results: A long lived, epigenetically and metabolically programmed eosinophil subset drove chronic AR. Post acute inflammation resolution, eosinophil precursors exhibited elevated chromatin accessibility at Alox5, Il4ra, Pparg, and Csf2rb, forming persistent epigenetic imprinting. These eosinophils underwent PPARγ dependent fatty acid oxidation (FAO) reprogramming, with prolonged survival, reduced apoptosis, and heightened sensitivity to IL 33/C5a, promoting robust IL 4/IL 13 and LTC4 release. Targeted eosinophil depletion or IL 33–ST2 blockade relieved nasal inflammation and allergic symptoms. Consistently, severe AR patient eosinophils displayed enhanced FAO and ALOX5 accessibility, which positively correlated with LTC4 production. Conclusion: Eosinophil innate immune memory via epigenetic and metabolic reprogramming sustains chronic AR. This conserved pathogenic signature provides a candidate biomarker for patient stratification and novel therapeutic targets for refractory upper airway allergy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →